Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies
Open Access
- 11 June 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 649122
- https://doi.org/10.3389/fimmu.2021.649122
Abstract
Thromboplasminflammation in coronavirus disease 2019 (COVID-19) coagulopathy consists of angiotensin II (Ang II)-induced coagulopathy, activated factor XII (FXIIa)- and kallikrein, kinin system-enhanced fibrinolysis, and disseminated intravascular coagulation (DIC). All three conditions induce systemic inflammation via each pathomechanism-developed production of inflammatory cytokines. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) downregulates angiotensin-converting enzyme 2, leading to an increase in Ang II levels. Ang II-induced coagulopathy comprising platelet activation, thrombin generation, plasminogen activator inhibitor-1 expression and endothelial injury causes thrombosis via the angiotensin II type 1 receptor. SARS-CoV-2 RNA and neutrophil extracellular trap (NET) DNA activate FXII, resulting in plasmin generation through FXIIa- and kallikrein-mediated plasminogen conversion to plasmin and bradykinin-induced tissue-type plasminogen activator release from the endothelium via the kinin B2 receptor. NETs induce immunothrombosis at the site of infection (lungs), through histone- and DNA-mediated thrombin generation, insufficient anticoagulation control, and inhibition of fibrinolysis. However, if the infection is sufficiently severe, immunothrombosis disseminates into the systemic circulation, and DIC, which is associated with the endothelial injury, occurs. Inflammation, and serine protease networks of coagulation and fibrinolysis, militate each other through complement pathways, which exacerbates three pathologies of COVID-19 coagulopathy. COVID-19 coagulopathy causes microvascular thrombosis and bleeding, resulting in multiple organ dysfunction and death in critically ill patients. Treatment targets for improving the prognosis of COVID-19 coagulopathy include thrombin, plasmin, and inflammation, and SARS-CoV-2 infection. Several drugs are candidates for controlling these conditions; however, further advances are required to establish robust treatments based on a clear understanding of molecular mechanisms of COVID-19 coagulopathy.Funding Information
- Japan Society for the Promotion of Science
This publication has 156 references indexed in Scilit:
- Recombinant Thrombomodulin Protects Mice against Histone-Induced Lethal ThromboembolismPLOS ONE, 2013
- Inhibition of TGF-β Signaling Enables Human Corneal Endothelial Cell Expansion In Vitro for Use in Regenerative MedicinePLOS ONE, 2013
- A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsisCritical Care, 2013
- Sensing of RNA Viruses: a Review of Innate Immune Receptors Involved in Recognizing RNA Virus InvasionJournal of Virology, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Histones induce rapid and profound thrombocytopenia in miceBlood, 2011
- Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4Blood, 2011
- Differential Downregulation of ACE2 by the Spike Proteins of Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus NL63Journal of Virology, 2010
- Harmful molecular mechanisms in sepsisNature Reviews Immunology, 2008
- Extracellular RNA constitutes a natural procoagulant cofactor in blood coagulationProceedings of the National Academy of Sciences of the United States of America, 2007